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Summary
Background:  This  study  was  designed  to  study  the  patient  characteristics,  presenting
features  and  complications  of  malaria  in  patients  with  elevated  liver  enzymes  and
to  compare  these  data  to  those  of  patients  with  normal  liver  enzymes.
Methods:  A  convenient  sample  of  100  patients  with  malaria  was  selected  from  three
tertiary  care  referral  hospitals.  Study  subjects  were  divided  into  two  groups:  (1)
patients  (controls)  with  normal  liver  enzymes  and  (2)  patients  (cases)  with  >3  times
the  normal  liver  enzymes  in  the  absence  of  an  alternate  explanation  for  such  ele-
vation.  Patient  characteristics,  presenting  features  and  complications  of  malaria
in  these  two  groups  were  studied.  Data  were  collected  using  a  semi-structured
pretested  proforma  and  were  analyzed  using  the  statistical  analysis  program  SPSS,
version  11.5  (SPSS,  Inc.,  Chicago,  IL).
Results:  The  mean  ages  were  38.12  years  for  the  cases  and  35.20  years  for  the
controls  with  a  non-signiﬁcant  p  value  of  0.289.  Males  composed  82%  of  the  cases
that  were  diagnosed  with  malarial  hepatopathy;  the  remaining  18%  were  females.
Falciparum  malaria  was  present  in  56%  of  the  cases,  compared  to  12%  of  the  controls.
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Icterus  was  present  in  66%  of  cases  of  malarial  hepatopathy,  compared  to  32%  of  the
controls.  Of  the  66%  of  these  cases,  18.18%  had  serum  bilirubin  >3  mg%,  whereas  out
of  the  32%  of  the  controls  presenting  with  icterus,  only  5.55%  had  serum  bilirubin
>3  mg%  (p  =  0.003).  Of  the  cases  with  malarial  hepatopathy,  38%  suffered  from  hypo-
glycemia,  compared  to  0%  of  the  controls  (p  <  0.001);  84%  of  the  cases  presented  with
thrombocytopenia,  compared  to  70%  of  the  controls  (p  <  0.001);  12%  of  the  cases  suf-
fered  from  renal  failure  with  serum  creatinine  levels  >2  mg%,  compared  to  2%  of  the
controls  (p  =  0.060).
Conclusion:  Plasmodium  falciparum  infection  (either  alone  or  along  with  P.  vivax)
is  the  leading  cause  of  malarial  hepatopathy.  Jaundice  is  a  common  clinical  mani-
atients.  Patients  with  malarial  hepatopathy  have  increased
mia  and  thrombocytopenia.  Malarial  hepatopathy  occurs  in
ion,  most  of  which  are  treated  with  parenteral  artesunate.
dulaziz  University  for  Health  Sciences.  Published  by  Elsevier
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(4)  Patients  <20  years  old.
A convenient  sample  of  100  patients  was  consid-festation  among  these  p
incidences  of  hypoglyce
relation  to  severe  infect
©  2013  King  Saud  Bin  Ab
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Introduction
Malaria  is  endemic  in  over  91  countries,  setting
at risk  approximately  40%  of  the  world  population
[1].  The  disease  accounts  for  500  million  clinical
cases and  more  than  a  million  deaths  per  year  [2];
it is  a  major  public  health  problem  in  developing
countries and  inﬂicts  a  huge  health  care  burden  in
terms of  morbidity  and  mortality  [3—5].
Malarial  hepatitis  is  characterized  by  hyper-
bilirubinemia  (>3  mg/dl)  and  elevated  transaminase
enzymes of  up  to  more  than  3 times  the  normal
levels [6].  Adherence  of  parasitized  erythrocytes
to the  endothelial  walls  of  liver  capillaries  leads
to the  blockade  of  intrahepatic  channels,  caus-
ing alterations  in  blood  ﬂow  and,  consequently,
ischemia.  As  a  result,  complications  such  as
hepatic encephalopathy,  multiorgan  failure  and
impaired  protein  synthesis  occur.  Histopatholog-
ical studies  have  revealed  hepatocyte  necrosis,
cholestasis, granulomatous  lesions  and  malarial
nodules [7].
According  to  the  World  Health  Organization,
signs of  malarial  hepatopathy  are  unusual  in  cases
of malaria  [8]. However,  in  recent  years,  signs  of
liver involvement  have  been  increasingly  reported
in Asian  countries,  especially  India,  with  a  major-
ity of  cases  suffering  from  falciparum  malaria
or mixed  (both  falciparum  and  vivax)  malaria
[8].  Cases  with  altered  liver  function  tests  and
even  fulminant  hepatic  failure  have  been  reported
[9,10].  A  study  conducted  on  Nigerian  children  con-
cluded that  the  increased  levels  of  liver  enzymes
are biochemical  features  of  Plasmodium  falci-
parum parasitemia  [11]. However,  the  data  on
malarial hepatopathy  is  still  sparse  in  the  liter-
ature.  This  study  was  designed  to  evaluate  the
patient  characteristics,  presenting  features  and
e
o
j
aomplications  of  malaria  in  patients  with  elevated
iver enzymes  and  to  compare  these  character-
stics to  those  of  patients  with  normal  liver
nzymes.
aterials and methods
his  study  was  performed  in  three  tertiary  care
eferral hospitals  in  Mangalore,  a  malaria  endemic
oastal  city  in  South  India.  These  hospitals  cater
o a large  number  of  patients  with  malaria.  Adult
atients  presenting  with  fever  who  tested  positive
or malaria  in  a  peripheral  smear  were  enrolled  in
he study.
Inclusion  criteria:
1)  The  ﬁrst  group  (controls)  of  patients  included
those suffering  from  malaria  but  who  had  nor-
mal liver  enzymes.
2) The  second  group  (cases)  included  those
patients who  had  elevated  liver  enzymes  (>3
times the  normal  levels)  due  to  malaria.
Exclusion  criteria:
1)  Patients  suffering  from  malaria  and  viral  hep-
atitis A,  B,  C,  D  and  E or  viral  hepatitis  alone.
2) Patients  presenting  with  increased  liver
enzymes with  conditions  such  as  sepsis,  drug-
induced increase  in  liver  enzymes  or  other
similar conditions.
3) Alcoholics.red. Institutional  Ethics  Committee  approval  was
btained  at  the  ﬁrst  author’s  institute.  Study  sub-
ects were  divided  into  two  groups  as  mentioned
bove under  the  inclusion  criteria.  They  were
Clinical  proﬁle  and  complication  of  malaria  hepatopathy  385
Figure  1  Gender  distribution  among  the  study  popula-
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Figure  2  Incidence  of  different  types  of  malaria
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A  total  of  66%  of  cases  of  malarial  hepatopathy
presented  with  icterus,  compared  to  32%  of  the
controls  (Fig.  4).  Out  of  these  66%  of  cases,  18.18%ion  classiﬁed  as  cases  and  controls.
nformed  about  the  details  of  the  study,  and  writ-
en informed  consent  was  obtained.  Hypoglycemia
as deﬁned  in  the  study  as  fasting  blood  sugar
FBS) <70  mg/dl.  Data  were  collected  using  a  semi-
tructured  pretested  proforma  and  were  analyzed
sing the  statistical  analysis  program  SPSS,  version
1.5 (SPSS,  Inc.,  Chicago,  IL).  p-Values  of  less  than
.05 were  considered  signiﬁcant.
esults
ge
atients  of  all  age  groups  above  20  years  were
nrolled in  the  study,  as  mentioned  in  the  inclusion
riteria, with  maximum  ages  of  64  amongst  cases
nd 77  amongst  controls.  The  mean  ages  were  38.12
ears in  the  cases  and  35.20  years  in  the  controls,
ith a  non-signiﬁcant  p  value  of  0.289.
ex
ales  composed  82%  of  the  cases  that  were  diag-
osed  with  malarial  hepatopathy;  the  remaining
8% were  females.  In  contrast,  68%  of  the  controls
ere males,  compared  to  32%  females  (p  =  0.106).
hese statistics  are  illustrated  in  Fig.  1.
omparison of the incidences of different
ypes of malaria
s  can  be  seen  from  Fig.  2,  56%  of  the  cases  had  fal-
iparum  malaria,  compared  to  12%  of  the  controls.
dditionally, 32%  of  the  cases  had  vivax  malaria,
ompared to  72%  of  the  controls,  and  12%  of  the
ases had  mixed  malaria  (due  to  both  P.  falciparum
F
smongst  cases  and  controls.
nd  P.  vivax),  compared  to  16%  of  the  controls.
p <  0.001).
resenting complaints
n  total,  100%  of  the  study  subjects  in  both  the  cases
nd the  controls  presented  with  fever  with  or  with-
ut associated  complaints.  As  can  be  seen  in  Fig.  3,
6% of  cases  had  fever  associated  with  chills,  com-
ared to  28%  of  the  controls,  10%  of  each  of  the
ases and  controls  had  fever  with  body  aches,  6%
f cases  had  fever  associated  with  headache,  com-
ared to  8%  of  the  controls  and  4%  of  cases  had
ever with  vomiting,  compared  to  6%  of  the  controls
Fig.  3).
omparison of bilirubinigure  3  Comparison  of  presenting  complaints  of  the
ubjects  between  the  cases  and  the  controls.
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Table  1  Incidence  of  thrombocytopenia  in  malaria  subjects  with  and  without  hepatic  involvement.
Vivax  malaria  with
thrombocytopenia
Falciparam  malaria
with
thrombocytopenia
Mixed  malaria  with
thrombocytopenia
Cases  11  24  7
Controls  26  3  6
Figure  4  Comparison  of  icterus  amongst  cases  and  con-
19  cases  (84.21%)  suffering  from  hypoglycemia  had
falciparum  malaria  or  mixed  malaria.
Correlation of thrombocytopenia with
malarial hepatopathy
Out  of  the  50  subjects  in  each  group,  42
(84%) of  the  cases  presented  with  thrombocy-
topenia, compared  to  35  (70%)  of  the  controls
(p <  0.001)  (Table  1).  The  mean  platelet  counts
were 73,269.60  ±  38,720.87350  for  the  cases  and
112,300.00  ±  65,178.32681  for  the  controls.
Correlation of renal failure to malarial
hepatopathy
A  total  of  12%  of the  cases  (6  out  of  50)  suffered
from renal  failure  with  serum  creatinine  levels
>2 mg%,  compared  to  2%  of  the  controls  (p  =  0.060).
This is  shown  in  Fig.  6.
Correlation of treatment received to
patients with malarial hepatopathy
Patients  received  oral  chloroquine  and  primaquine,trols.
had  serum  bilirubin  >3  mg%,  whereas  out  of  the  32%
of controls  presenting  with  icterus,  only  5.55%  had
serum bilirubin  >3  mg%  (p  = 0.003).
Comparison of hypoglycemia amongst cases
and controlsAs  seen  in  Fig.  5, 38%  of  the  cases  with  malarial  hep-
atopathy  suffered  from  hypoglycemia,  compared  to
0% of  the  controls  (p  <  0.001).  Sixteen  out  of  the
Figure  5  Comparison  of  hypoglycemic  events  amongst
cases  and  controls.
oral artesunate  or  intravenous  artesunate  based
on malaria  type  and  disease  severity.  In  general,
only 22%  of  patients  with  malarial  hepatopathy
Figure  6  Comparison  of  renal  failure  amongst  cases  and
controls.
Clinical  proﬁle  and  complication  of  malaria  hepatopath
F
a
r
t
o
q
o
w
q
o
t
c
D
I
b
w
b
t
8
v
d
N
f
I
m
m
p
c
s
c
a
i
c
i
s
i
t
h
s
s
i
a
e
i
w
f
l
t
s
p
t
4
t
i
i
t
d
e
t
n
m
s
s
O
m
t
a
S
s
p
s
bigure  7  Comparison  of  treatment  received  by  cases
nd  controls.
eceived  oral  drugs,  compared  to  80%  of  the  con-
rols (p  < 0.001).  As  seen  in  Table  2,  10%  of the  22%
f the  cases  taking  oral  therapy  were  on  oral  chloro-
uine  and  primaquine,  and  the  rest  (12%)  were  on
ral artesunate.  Of  the  controls,  46%  out  of  the  80%
ho were  taking  oral  therapy  were  on  oral  chloro-
uine and  primaquine,  and  the  rest  (34%)  were  on
ral artesunate.  Intravenous  artesunate  was  given
o 78%  of  the  cases,  compared  to  only  20%  of  the
ontrols (Fig.  7).
iscussion
n  this  study,  adults  of  all  age  groups  were  affected
y malaria.  The  most  common  age  group  involved
as 21—30  years.  A  similar  age  incidence  was  noted
y Muddaiah  et  al.  in  2006  [12]. Cases  and  con-
rols were  predominantly  male,  which  made  up
2% and  68%  of  the  group  populations,  respectively,
ersus 18%  and  32%  females.  Previous  studies  con-
ucted in  South  Canara,  South  India  and  Punjab,
orth  India  had  concluded  that  males  outnumbered
emales for  reasons  that  remain  unclear  [12,13].
n the  present  study,  the  majority  of  patients  with
alarial  hepatopathy  suffered  from  falciparum  and
ixed infections.  Although  P.  vivax  is  the  major
arasite type  that  causes  malaria,  most  malaria
omplications are  due  to  P.  falciparum  [12]. In  a
tudy conducted  in  North  India  [13],  it  was  con-
luded  that  hepatic  involvement  was  a  common
t
8
p
s
Table  2  Group-wise  distribution  of  the  treatment  received
Oral  chloroquine  and  primaquine  (%)  
Cases  (n  =  50)  10  
Controls  (n  =  50)  46  y  387
ccompaniment  of  acute  falciparum  malaria,  which
s in  accord  with  our  study,  the  results  of  which  indi-
ated that  P.  falciparum  (either  causing  infection  by
tself or  along  with  P.  vivax)  was  the  most  common
pecies of  Plasmodium  that  caused  a  three-fold  rise
n liver  transaminase  levels.
This study  suggested  a very  signiﬁcant  correla-
ion between  elevated  bilirubin  levels  and  malarial
epatopathy.  Among  the  cases,  66%  of  subjects  pre-
ented with  icterus,  compared  to  only  32%  of  the
ubjects  among  the  controls  (p  =  0.003).  This  ﬁnding
s in  accord  with  a  study  by  Kausar  et  al.  [14],  which
lso established  positive  correlations  between  liver
nzymes and  bilirubin  levels.  In  a study  conducted
n the  United  Arab  Emirates  from  2005  to  2007,  it
as concluded  that  hepatic  dysfunction  in  acute
alciparum  malaria  ranged  from  mild  elevations  of
iver enzymes  to  acute  hepatitis  (alanine  amino-
ransferase  [ALT]  >10  times  the  normal  level).  A
igniﬁcant  ﬁnding  in  that  study  indicated  that  87.5%
atients with  conjugated  bilirubin  levels  greater
han  3 mg/dl  had  increased  ALT  levels;  in  contrast,
5% patients  with  conjugated  bilirubin  levels  less
han 3  mg/dl  had  increased  ALT  levels,  suggest-
ng a  positive  correlation  between  bilirubin  and
ncreasing  liver  enzyme  levels  [15]. Liver  func-
ion tests  should  be  performed  along  with  early
iagnosis of  P.  falciparum  malarial  infections  to
nsure the  early  diagnosis  of  malarial  hepatopa-
hy.
The present  study  also  established  a very  sig-
iﬁcant  correlation  between  hypoglycemia  and
alarial hepatopathy  (p  <  0.001).  Of  the  cases,  38%
uffered from  hypoglycemia  with  a  fasting  blood
ugar  <70  mg/dl,  compared  to  0%  of  the  controls.
f these  patients,  84.21%  suffered  from  falciparum
alaria. Hence,  patients  with  malarial  hepatopa-
hy, especially  with  P.  falciparum  infection,  have
n increased  chance  of  developing  hypoglycemia.
tudies conducted  in  Dakar  [16]  and  Mali  [17]  have
hown that  hypoglycemia  in  severe  malaria  is  a  poor
rognostic  factor,  with  increased  mortality  rates  in
uch cases.
Similarly,  a  signiﬁcant  correlation  was  observed
etween thrombocytopenia  and  malarial  hepatopa-
hy. Of  the  patients  with  malarial  hepatopathy,
4% had  thrombocytopenia  in  our  study,  com-
ared to  only  70%  of  the  controls  (p  <  0.001).  One
tudy  conducted  in  North  India  [10]  that  compared
 by  the  case  and  control  subjects.
Oral  artesunate  (%)  Intravenous  artesunate  (%)
12  78
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thrombocytopenia  to  serum  bilirubin  established
that the  incidence  of  thrombocytopenia  in  patients
with serum  bilirubin  >10  mg%  was  found  to  be  higher
than  in  patients  with  bilirubin  levels  <3  mg%.
There  was  no  signiﬁcant  correlation  between
acute renal  failure  and  malarial  hepatopathy
(p = 0.06).
Most  of  the  patients  with  malarial  hepatopa-
thy were  put  on  intravenous  artesunate  or  oral
artesunate,  depending  on  disease  severity.  This
approach  is  based  on  data  suggesting  that  arte-
sunate is  superior  to  intravenous  quinine  for  the
treatment  of  adults  with  severe  malaria  in  Asia  [18].
Our study  had  a  few  limitations.  First,  the
sample size  was  relatively  small,  involving  only
100 patients.  Second,  the  subjects  were  not  fol-
lowed  up  for  the  possible  chronicity  of  their  liver
disease. Similarly,  we  did  not  analyze  the  time
trend for  the  resolution  of  hepatopathy  since
the initiation  of  therapy.  Additionally,  the  corre-
lation between  parasite  burden  and  severity  of
hepatopathy  was  not  analyzed.  However,  it  is
difﬁcult to  imagine  a  composite  research  study
focusing  on  the  rare  incidence  of  malarial  hep-
atopathy, and  we  have  attempted  to  associate  the
complications  likely  to  be  present  in  malarial  infec-
tions to  the  increased  liver  enzyme  levels  in  the
patients.
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